Clinical trial · Observational
Precision Medicine in the Prostate Cancer Care Pathway
Precision Medicine in the Prostate Cancer Care Pathway: an Evaluation of Integrating Germline Genetic Testing Into the Management of Men at Risk of / Living With Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genetic Predisposition | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostate cancer risk gene panel | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- AFFECTED
- description
- 1. Affected with PrCa \<60 years 2. Affected with metastatic castration resistant PrCa (mCRPC) or aggressive PrCa (Gleason 4+4 or higher \<70 years 3. Affected with PrCa and a family history defined as three or more cases any age (FDR or SDR)
- interventionNames
- Genetic: Prostate cancer risk gene panel
- label
- UNAFFECTED (Cohort now closed, recruitment complete)
- description
- \- Aged \>30 and with a family history defined as:: 1. FDR diagnosed \< 70 2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years 3. 3 or more cases at any age (on same side of family)
- interventionNames
- Genetic: Prostate cancer risk gene panel
Primary outcomes (1)
- measure
- Prevalence of genetic variation in affected men
- timeFrame
- Through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Affected cohort: 1. Affected with PrCa \< 60 years or 2. Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70 years 3. Affected with family history defined as three or more cases any age (FDR or SDR) Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment) Aged \>30 and with a family history defined as: 1. FDR diagnosed \< 70 2. 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed \< 70 years 3. 3 or more cases at any age (on same side of family) Exclusion Criteria: * • WHO performance status 4
References
Publications (0)
Data not yet available